1800 244 735

Helpline (02) 9874 9777

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam.

An existing drug…for huntingtin lowering?

The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to branaplam for treatment of Huntington’s disease.

Branaplam was originally developed for the treatment of the neurological disorder spinal muscular atrophy (SMA) and is still under clinical investigation for this purpose. Branaplam works by interfering with how genetic messages are processed in cells and can increase the levels of a protein called SMN2. Boosting levels of SMN2 helps SMA patients who have lower levels of this protein which is the underlying cause of the disease in many cases.

Interestingly, it seems that branaplam also reduces the levels of the huntingtin gene message and the huntingtin protein. This is what huntingtin-lowering therapies all aim to do and is how many researchers and companies hope to treat Huntington’s disease.

The huntingtin-lowering therapies currently in clinical trials need to be given through spinal injections or brain surgery. Unlike these, branaplam is a small molecule drug, which means it can be taken as a tablet. If Novartis can show that branaplam is an effective treatment for HD, this would mean that it could be given as a pill, a more convenient option for HD patients!

Orphan Drug Designation – and what’s next

The FDA’s decision to grant orphan drug status is usually done when a medicine is being developed for the treatment of a rare disease like Huntington’s disease. Granting orphan drug status can provide benefits and incentives to the company who has developed the drug, in this case Novartis, to encourage the development of new medicines for diseases with only a small population of patients.

There is still a lot that scientists don’t understand about using branaplam to treat HD patients. Pill-based treatments are expected to work on the whole body, not just the brain and it is not very clear what the effects of lowering huntingtin everywhere might be. Additionally, we already know that branaplam can alter the levels of both SMN2 and huntingtin so it is probably the case that levels of other proteins might also change with branaplam treatment. Without a complete and precise understanding of what scientists call the “mechanism of action” of a drug, this could make it complicated to work out exactly how branaplam treatment might alter HD symptoms. The good news is that the drug has already been shown to be safe in small groups of SMA patients.

Novartis is now designing a Phase II clinical trial for patients with HD, which is planned for launch in 2021. We hope to bring you more updates soon!

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Meeting 2021

Published date: 28 October, 2021

Last month, the Huntington’s disease (HD) research community, patients and other stakeholders met online at the European Huntington’s disease network (EHDN) conference. Despite the ongoing global pandemic, there is a tremendous amount of work underway in labs and clinics around the world as researchers continue to better understand HD and how we might best treat ... Read more

Real talk: Q&A with Roche about GENERATION-HD1

Published date: 28 September, 2021

At the end of day 1 of the European Huntington’s Disease Network (EHDN) conference, the HDBuzz team (minus one) sat down for a zoom chat with the team at Roche to have a frank, candid discussion about the recent halting of GENERATION-HD1, the Phase 3 clinical trial that was testing the ability of the antisense ... Read more

Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing

Published date: 30 August, 2021

A team of scientists recently created an innovative genetic system where a drug taken by mouth could be used to control the action of a gene editor, like those used in CRISPR systems. This has useful applications for research studies in cells and animals, and perhaps most importantly, could lead to improvements in the safety ... Read more

Unpacking recent gene therapy press

Published date: 16 August, 2021

A recent announcement from Voyager Therapeutics outlined a shift in the company’s strategy towards an exciting new technology for gene therapy delivery. Unfortunately this also means that in the short term, they have dropped previous plans to test an HD gene therapy in people with HD. While this news is disappointing, the decision to embrace ... Read more

Does blood hold the key to testing treatments earlier in HD patients?

Published date: 4 August, 2021

Researchers at Johns Hopkins led by Wenzhen Duan have developed a non-invasive way to track progression of Huntington’s disease (HD) which could be used before patients even start showing symptoms. Using a type of brain scan called an MRI, the researchers have shown that in mouse models of HD they can accurately measure the amount ... Read more

A first for CRISPR gene editing could have wider applications for human disease

Published date: 21 July, 2021

A recent clinical trial successfully tested the safety of CRISPR gene editing to reduce the amount of a toxic protein in patients with Familial Transthyretic (TTR) Amyloidosis. Although this study is unrelated to Huntington’s disease, it’s a first for gene editing, and the results could have implications for HD and other brain disorders. CRISPR-Cas9 Clustered ... Read more